Tech Transfer eNews Blog
University-Industry Engagement Advisor

Y2X Life Sciences and Washington U sign option agreement to commercialize SARS-CoV-2 detection technology

By Jesse Schwartz
Published: September 15th, 2021

New York-based Y2X Life Sciences and Washington University in St. Louis (WUSTL) have entered into an option agreement for an exclusive license to commercialize a technology that can detect aerosolized SARS-CoV-2.

Developed by researchers at WUSTL, the biosensor technology is able to detect very low amounts of the virus and could be applied to large gathering places such as airports, music venues, government buildings, schools and more.

“We are pleased to partner with Y2X Life Sciences to bring this important technology out of the laboratory and into devices that can help save lives,” says John Cirrito, professor at WUSTL and co-inventor of the biosensor. “This technology was put through rigorous diligence as part of the NIH grant process and is an example of the strength of our research programs and collaboration between our Schools of Medicine and Engineering.”

David Shuler, president and co-founder of Y2X Life Sciences, comments, “This technology is unique for its ability to detect very low amounts of virus, including SARS-CoV-2 and, in the future, other pathogens. We are very excited to work with Washington University to expedite development of this core technology and, in collaboration with our partners, initiate testing to secure regulatory approvals and fulfill Y2X Life Science’s mission of providing safe environments.”

Source: Business Wire

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment